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Abstract 35 
The oral vaccination of wild badgers (Meles meles) with live Bacillus Calmette–Guérin 36 
(BCG) is one of the tools being considered for the control of bovine tuberculosis (caused 37 
by Mycobacterium bovis) in the UK. The design of a product for oral vaccination requires 38 
that numerous, and often competing, conditions are met. These include the need for a 39 
highly palatable, but physically stable bait that will meet regulatory requirements, and one 40 
which is also compatible with the vaccine formulation; in this case live BCG. In 41 
collaboration with two commercial bait companies we have developed a highly attractive 42 
and palatable bait recipe designed specifically for European badgers (Meles meles) that 43 
meets these requirements. The palatability of different batches of bait was evaluated 44 
against a standardised palatable control bait using captive badgers. The physical 45 
properties of the bait are described e.g. firmness and colour. The microbial load in the bait 46 
was assessed against European and US Pharmacopoeias. The bait was combined with an 47 
edible vaccine carrier made of hydrogenated peanut oil in which BCG vaccine was stable 48 
during bait manufacture and cold storage, demonstrating <0.5 log10 reduction in titre after 49 
117 weeks’ storage at 20 C. BCG stability in bait was also evaluated at +4 C and under 50 
simulated environmental conditions (20 C, 98% Relative Humidity; RH). Finally, 51 
iophenoxic acid biomarkers were utilised as a surrogate for the BCG vaccine, to test 52 
variants of the vaccine-bait design for their ability to deliver biomarker to the 53 
gastrointestinal tract of individual animals. These data provide the first detailed description 54 
of a bait vaccine delivery system developed specifically for the oral vaccination of badgers 55 
against Mycobacterium bovis using live BCG 56 
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1. Introduction 59 
The package of control measures aimed at the eradication of bovine tuberculosis (TB) in 60 
England and Wales includes the development of an oral vaccine for badgers (Meles 61 
meles) against the causative agent, Mycobacterium bovis [1]. The first injectable vaccine 62 
for TB in badgers, BadgerBCG, was licensed in 2010 and has been used in specific areas 63 
of England and Wales since then [2,3]. The beneficial effects of the injectable vaccine 64 
have been demonstrated in terms of reducing disease severity and progression in captive 65 
badgers and reduced serological evidence of infection in wild badgers [4]. The major 66 
limitation of BadgerBCG is the need to trap badgers to inject the vaccine. A cost-effective 67 
BCG-based oral vaccine could achieve wider coverage, overcoming some of the financial 68 
and logistical issues associated with the widespread deployment of BadgerBCG [5]. Oral 69 
vaccines against TB are in development for a number of wildlife species besides badgers 70 
[6–9]. In all cases, the development and delivery of a licensed oral vaccine product to the 71 
field faces many challenges, including effective delivery of the vaccine by consumption, 72 
vaccine stability, and environmental safety [10]. These are best exemplified by the 73 
comprehensive programme of research and development of the oral rabies vaccine for 74 
foxes (Vulpes vulpes) in Europe [11], the end product being a ‘tailor-made’ species-75 
specific bait-vaccine product that can be manufactured and deployed at scale. Oral 76 
vaccine delivery mechanisms developed for one species are not necessarily appropriate 77 
for another, even if the product is palatable. For example, a bait-vaccine carrier developed 78 
for wild boar (Sus scrofa) was also attractive to badgers in Spain, but of 150 baits 79 
consumed by badgers, 87% had the vaccine carriers (plastic capsules) rejected and of 80 
these, 99% were separated from the bait intact with the payload of water still inside [12]. 81 
Here we present the first detailed description of a vaccine delivery system developed 82 
specifically for the oral vaccination of badgers with live BCG. Numerous baits and possible 83 
vaccine carriers were trialed with both captive and wild badgers. Captive animals were 84 
used to screen large numbers of different products of which some were selected for field-85 
testing; only selected data are presented here. The selection of the best bait was 86 
dependent on many factors including the potential for ease of manufacture at relatively low 87 
cost, as well as the results of associated field studies. The data we present are crucial for 88 
the on-going development and eventual licensing of an oral vaccine product for badgers, 89 
including: (a) identification and description of important physical characteristics of the bait 90 
for potential future quality control (QC) purposes for large-scale manufacture; (b) design of 91 
a bait with a compatible and palatable vaccine carrier; (c) evidence that the bait-vaccine 92 
carrier design can deliver biomarker to the GIT of badgers as a surrogate for BCG; and (d) 93 
evidence that the BCG vaccine remains viable in the delivery system through laboratory 94 
production processes, cold-storage and simulated field conditions. 95 
 96 
2. Materials & Methods 97 
2.1 Animals 98 
Badgers were either brought in from the wild from TB-free areas under licence, or born in 99 
captivity. Wild-caught animals were demonstrated to be free of TB on the basis of IFN 100 
and clinical sample culture testing and housed in groups (two to five animals per pen) in 101 
open-air pens with artificial setts, as described elsewhere [13]. Animals were fed a mixture 102 
of commercial dog food, peanuts and occasionally fruit and specified pathogen-free eggs. 103 
Each pen was equipped with a motion-sensitive infra-red CCTV camera (Secom Security 104 
Systems PLC., Kenley, UK). Groups of two to five penned animals were used in 105 
palatability and bait design tests as animals could not be repeatedly housed individually for 106 
animal welfare reasons; animals were individually caged for a single night for the 107 
biomarker study only. The work was carried out under licences (PL 70/6864 and PL 108 
70/7878) from the UK Home Office under the Animal (Scientific Procedures) Act 1986 and 109 
approved by the Animal and Plant Health Agency (APHA) Local Ethical Review Panel. 110 
2.2 QC of the bait components 111 
The bait (referred to as either ‘PT’ or ‘paste bait’), is based on a proprietary recipe and was 112 
developed with Pest-Tech Ltd. (Leeston, New Zealand) and Connovation Ltd. (Manukau, 113 
New Zealand). The paste is free of anti-microbial preservatives, genetically-modified 114 
organisms or animal-derived products. Two physical attributes, namely firmness and 115 
colour, were assessed for batches of paste bait post-production. Firmness measurements 116 
(kgf) were obtained using a calibrated fruit pressure tester (FT011 with 8 mm tip; ACE 117 
Supplies Industrial Ltd., Staplehurst, UK) applied to a minimum of three bait portions (~11 118 
g) from each batch. Colour was visually assessed by comparison with a colour chart [14] 119 
and the closest match recorded for each batch. Between one and three samples of paste 120 
bait from each batch were submitted for microbiological testing (Wickham Laboratories 121 
Ltd., Gosport, UK) as soon as possible after manufacture to assess microbial burden 122 
against the European pharmacopoeia (EP) and US pharmacopoeia (USP) specifications 123 
for ‘Non-aqueous preparations for oral use’: (a) total aerobic microbial count (TAMC) and 124 
total yeast and mould count (TYMC) with limits of ≤2x103 and ≤2x102 CFU g-1 of bait, 125 
respectively; and (b) the absence of Escherichia coli in 1 g of material. Where more than 126 
one sample was tested per batch of bait, if any one sample exceeded any of the EP or 127 
USP specifications, it was considered to have failed QC. Three batches of the vaccine-128 
carrier material, a solid, edible vegetable lipid (HPO, hardened [hydrogenated] peanut oil; 129 
Ph. Eur., Sigma-Aldrich Company Ltd., Gillingham, UK) were also submitted for 130 
microbiological testing against EP and USP criteria. Palatability testing of the paste bait 131 
was carried out between April and October, in both 2013 and 2014, in order to avoid the 132 
winter months when badgers exhibit reduced activity [15] and to correspond to when oral 133 
bait vaccine would most likely be deployed in the field. In each test (one test per batch of 134 
bait) between six and eight groups of animals were each presented with bait contained in 135 
five litre plastic tubs (two white and two grey), which were placed in a Latin square 136 
arrangement in each pen (tubs approx. 1 m from each other) in the late afternoon before 137 
the animals emerged from their setts. Two tubs contained 400 ± 1 g of a batch of paste 138 
bait each and two tubs contained 400 ± 1 g of control bait each, comprising a mix of 139 
peanuts and golden syrup (ratio 8:1), known to be highly palatable to badgers [16]. Tests 140 
were run overnight and normal feed was either withheld for the entire night or given to a 141 
group after they had consumed some, but not all, of either bait type; water was provided 142 
ad libitum. Limited consumption of bait by a group of animals (i.e. <20 g of one or both bait 143 
types, as recommended by the manufacturer) was not considered to be representative of a 144 
definitive preference and could result in incorrect palatability calculations. Therefore 145 
groups which consumed <20 g of material were not included in the palatability 146 
calculations. Palatability (%) was calculated for each group of animals by dividing the 147 
weight of test bait consumed by the total quantity of bait (test and control) consumed by 148 
the group. The final palatability value for a batch of bait was calculated by taking an 149 
average across all groups. The peanut and syrup control provided a benchmark for 150 
palatability, as a minimum standard for a palatable bait. Therefore any test material was 151 
required to be at least as palatable as the control i.e. have a palatability of ≥50%. 152 
However, a more stringent palatability threshold of 65% was set for this work to allow for 153 
the greater variability introduced when using a small number of groups for testing; ideally 154 
palatability tests would utilise large numbers of individually caged animals (R. Henderson, 155 
Pest-Tech Ltd., personal communication). 156 
2.3 Bait design tests: bait consumption 157 
Variants of the PT-HPO bait design (Fig. 1) were evaluated in two tests designed to 158 
investigate whether altering the PT:HPO ratio and varying the surface area of the exposed 159 
PT (to enhance odour release) affected bait disappearance and/or preference. Groups of 160 
captive animals were presented with bait portions under inverted terracotta plant pots (with 161 
a drainage hole in the base) placed on saucers. Baits, with each type under a different pot, 162 
were placed in the pens in the late afternoon prior to the animals emerging from their setts. 163 
The delivery of normal feed was delayed until 23:00 each night, to give the animals time to 164 
interact with the baits with no other food present. Infra-red CCTV footage of the night was 165 
then reviewed to determine (a) the numbers of baits taken - whether or not the bait was 166 
consumed in view of the cameras, and (b) preference as measured by the order in which 167 
different baits were taken (mean order baits taken across all groups). The peanut and 168 
syrup mix was prepared as described previously and presented in portions equal in weight 169 
to the baits presented in each pen. In test 1, three different designs of the PT-HPO bait 170 
(‘SH’, ‘M’ and ‘C’, Fig. 1), ranging in weight from 13 g to 16 g each, were presented to ten 171 
groups of animals (between three and five animals per group) over two nights in three-172 
choice tests. The different baits (one bait of each type per group) were rotated through 173 
each pen and each position, left to right, in view of the camera. Test 2 included the bait 174 
designs from test 1 and an additional two designs (‘T’ and ‘D’, Fig. 1) in a four-choice test. 175 
Bait designs were rotated through each group over three nights such that each potential 176 
bait combination was presented to each group. 177 
2.4 Bait design tests: biomarker delivery 178 
Two different iophenoxic acid (IPA) biomarkers (PR euroCHEM Ltd., Cork, Ireland) were 179 
incorporated into each of two bait designs (selected from those tested in tests 1 and 2 180 
above) in order to determine whether they could, irrespective of packaging type, deliver 181 
IPA to the GIT as a surrogate for the BCG vaccine. Each bait contained 80 ± 4 mg (±5%) 182 
of Propyl-IPA powder (P-IPA; a-propyl,b-(3- hydroxy-2,4,6-triiodo)phenyl-propionic acid) 183 
weighed directly into the centre of the bait within the HPO core in place of the BCG. 184 
Isobutyl-IPA (I-IPA; a-isobutyl,b-(3-hydroxy-2,4,6-triiodo)phenyl-propionic acid) was 185 
incorporated by evenly dissolving 80 mg throughout the HPO component to provide 186 
internal calibration for the amount of actual vaccine carrier consumed. A total of 20 187 
animals were presented with a single bait each and bait allocation was randomised. Ten 188 
were given the PT-HPO ‘M’ in a greaseproof paper bag (approx. 140 x 170 mm, 189 
Connovation Ltd.) and 10 were given the ‘SH’ bait packaged in a low density polyethylene 190 
(LDPE)-lined paper bag (approx. 90 x 170 mm). Different types of packaging were being 191 
evaluated in order to inform packaging field tests [17]. Materials such as plastic-lined 192 
paper may offer increased protection to the bait against moisture, relative to a paper bag. 193 
Individual animals were trapped overnight in cages with a single bait for one night only; 194 
water was provided in a bowl. Animals were released the following morning and any bait 195 
fragments found in the cages collected and weighed. Only animals that consumed some or 196 
all of the bait were anaesthetised by an intramuscular injection of ketamine and 197 
medetomidine (10 mg/kg; Vetalar® and 100 µg/kg; Domitor®, respectively; Pfizer Animal 198 
Health, New York, USA) and bled by jugular venepuncture into Serum Separation Tubes 199 
(SST Vacutainer tubes; BD, Plymouth, UK) 13–15 days after bait consumption, to coincide 200 
with peak IPA serum levels (based on unpublished findings). Serum samples were stored 201 
frozen (80 C) and submitted for duplicate analysis by liquid chromatography-mass 202 
spectrometry (LC-MSMS; LGC, Teddington, UK), to quantify and differentiate between P-203 
IPA and I-IPA. 204 
2.5 Stability of BCG in PT-HPO baits 205 
Following successful additional field testing as a carrier (K. Palphramand et al., 206 
unpublished results), and on the basis of ease of manufacture, the ‘SH’ and ‘M’ PT-HPO 207 
baits (Fig. 1) were used to test vaccine stability. A 200 µl volume of BCG vaccine 208 
suspension (Danish strain 1331; ‘Concentrated Bulk BCG’ preparation, Statens Serum 209 
Institute, Copenhagen, Denmark), was encapsulated within the centre of the HPO (Fig. 210 
1b). BCG stability (survival) within baits was evaluated at the storage temperatures of 20 211 
C and 4C without humidity control, and at 20 C at 98% relative humidity (RH) 212 
maintained using an environmental test chamber (THC Slimline 600/800/-40/ME; 213 
Sharetree Ltd., Stonehouse, UK). The conditions in the environmental chamber were 214 
based on RH measurements taken from badger setts by LogTag® recorders (HAXO-8; 215 
LogTag Recorders Ltd., Auckland, New Zealand) during a Spring-Summer bait 216 
deployment study (unpublished results) and from UK MET Office soil temperatures, as 217 
indicative of the conditions a product would experience if deployed down a sett entrance. 218 
BCG was extracted from baits at regular intervals by cutting each bait into small fragments 219 
to release the BCG from the centre. The fragments were submerged in Sauton liquid 220 
medium supplemented with 0.05% (v/v) Tween 80 and agitated to macerate the PT and 221 
wash the BCG from the fragments in order to form a suspension. Aliquots of this 222 
suspension and dilutions thereof were plated on Modified 7H11 agar plates and BCG 223 
colonies enumerated after four weeks’ incubation at 37 C. Log change values were 224 
calculated as log10 (CFU per bait) at each sampling point minus the value at the first time 225 
point for the storage conditions under evaluation. 226 
2.6 Statistical analyses 227 
Chi-squared tests were used to test whether badgers exhibited evidence of preference for 228 
particular bait types (measured as the order in which baits were consumed), or whether 229 
they simply selected different bait types at random. Correlations between mean P-IP and 230 
mean I-IPA values of individual badgers were tested using Pearson correlation tests. Chi-231 
square and correlation analyses were carried out using R 3.0.2 (cran.org). The numbers of 232 
badgers consuming ‘M’ and ‘SH’ bait types were compared using Fisher’s Exact Test (two-233 
tailed) performed in GraphPad Prism® 6 software (GraphPad Software, Inc., USA). 234 
3. Results 235 
3.1 QC of the bait components 236 
The firmness of the paste bait ranged between 1.8 and 3.2 kgf with a mean of 2.3 kgf 237 
(SEM 0.04 kgf; n = 87 tests for 16 batchesof bait). Of these 16 batches, two had TAMC in 238 
excess of 2 x 103 CFU g-1 but none had TYMC above the limit of 2 x 102 CFU g-1; E. coli 239 
was not detected in any of the samples. The three batches of HPO were all free of E. coli 240 
and all had TAMC of <1 x 101 CFU g-1 and TYMC of ≤5.0 x 100 CFU g-1. The colour of the 241 
paste bait was consistent between batches. Thirteen batches of paste bait were 242 
palatability tested and each batch was presented to 6–8 groups of animals. Overall mean 243 
palatability was 77% (67–87%) with none of the batches having a mean palatability of less 244 
than the 65% target threshold (Fig. 2). 245 
3.2 Bait design tests 246 
The percentage of baits taken in tests 1 and 2 was high for all designs (80–100%) and the 247 
order of bait selection was not significantly different from that expected if animals were 248 
selecting at random (Chi-squared tests, test 1 :
9
2= 6.67, p = 0.67, test 2: 
9
2 = 8.58, p = 249 
0.37). Of the bait designs, ‘SH’ and ‘M’ (Fig. 1), were selected for the biomarker study 250 
based on size, handling by the animals and ease of manufacture. The number of individual 251 
badgers consuming bait was 8/10 and 5/10 for the ‘M’ and ‘SH’ baits respectively (NS 252 
difference, Fisher’s Exact Test). Very few fragments were recovered post-consumption 253 
with their weight constituting 2.1% (n = 3) and 2.4% (n = 3) of the ‘M’ and ‘SH’ baits 254 
respectively. Every animal that consumed a bait had positive serum-IPA levels and mean 255 
serum values for P-IPA and I-IPA were closely correlated for the bait designs under 256 
evaluation (Pearson correlation, t25 = 6.98, p < 0.001, r = 0.81). 257 
3.3 BCG stability in PT-HPO baits 258 
The oral BCG dose required to successfully vaccinate badgers in the field is not known. In 259 
addition, storage, distribution and deployment of a commercial oral badger vaccine is likely 260 
to expose BCG-containing baits to a range of temperatures and for varying durations. For 261 
these reasons, the stability of BCG in bait was broadly characterised using a range of 262 
different starting concentrations, temperatures and durations: 2.90 x 106–1.32 x 108 263 
CFU/bait at20 C, 1.24 x 107 – 9.20 x 107 CFU/bait at 4 C and 5.40 x 107– 6.20 x 107 264 
CFU/bait at 20C and 98% RH. BCG-containing baits evaluated at 4C and 20 C 98% RH 265 
had previously been stored at 20C for between 4 and 207 days, and 25 days, 266 
respectively. BCG retained viability in bait best when stored at 20 C (Fig. 3a) with <0.5 267 
log10 decrease in CFU/bait up to 117 weeks storage. BCG was les s stable in bait when 268 
stored at 4 C or at 20 C, 98% RH, with notable and more rapid decreases in CFU/bait 269 
becoming apparent after approximately 7 days’ storage (Fig. 3b and c). The overall 270 
physical structure of the vaccine-baits remained intact over a 30-day period (Fig. 4). 271 
4. Discussion 272 
The data presented here fulfil the first important steps in the development and testing of a 273 
tailor-made oral vaccine product for UK badgers against TB, namely palatability, vaccine 274 
stability during bait manufacture and storage, determination of objective and descriptive 275 
criteria for QC, and demonstration of its ability to deliver biomarker after ingestion as a 276 
surrogate for the vaccine.  277 
The data generated from the QC of the paste bait not only allowed for a better definition of 278 
the product but also demonstrated, for the majority of the batches tested, a consistent 279 
standard of manufacture. This is important for future bait production but also reassuring 280 
given the nature of some of the key bait ingredients which are plant-derived and 281 
preservative-free and therefore more variable in nature than, for example, more highly 282 
processed products such as the HPO component that will carry the vaccine. Slight 283 
variations in paste-bait consistency and colour did not affect its palatability to captive 284 
animals as the material was consistently more palatable (on average, more paste bait was 285 
consumed than control bait in all batch tests; Fig. 2) to captive animals than the peanut-286 
syrup mix, which is known to be highly attractive to badgers. There are unavoidable 287 
limitations associated with the use of captive animals for bait tests, namely the limited 288 
sample size and the possible effects of an artificial diet on bait preference and 289 
consumption. However, promising materials were always field-tested and these tests 290 
reflected the high attractiveness and palatability of the PT-HPO baits observed with 291 
captive animals [17]. 292 
The paste bait component fulfils several important roles as an effective lure (release of 293 
olfactory cues), a palatable material and as an adaptable and malleable material 294 
compatible with a vaccine carrier (in this case HPO). Smell is a very important sense for 295 
badgers [18] and so the release of odour by the paste bait is likely to be important for 296 
attracting individuals to the bait which is why the bait designs (Fig. 1) varied in the surface 297 
area of exposed PT (that not covered by the HPO). The PT component may also help to 298 
mask the taste of the vaccine payload; PT-HPO baits containing 200 µl of BCG have 299 
proven palatable (88% and 92% of baits taken) with individually caged badgers in two 300 
vaccine efficacy trials (S. Lesellier, personal communication). In the current study, 301 
variations in bait design did not appear to affect attractiveness (percentage of baits taken) 302 
allowing bait design to be driven by other criteria including ease of manufacture, cost (as 303 
determined by the quantities of the ingredients) and physical stability; bait size did not 304 
affect preference as baits of different sizes were also readily accepted by wild badgers [17] 305 
(K. Palphramand et al., Unpublished results). 306 
The use of the IPA biomarkers demonstrated that irrespective of bait design, a core of 307 
biomarker could be ingested yielding a positive serum sample in every individual that 308 
consumed bait, thus complementing IPA-data from a vaccine carrier field study (K. 309 
Palphramand et al., unpublished results). In addition, very little of each bait was left behind 310 
in the cages of badgers which had consumed baits, which mirrors observations in the field 311 
that animals generally eat any bait fragments which fall from the mouth during 312 
consumption (K. Palphramand, personal communication); removal of bait fragments by 313 
badgers would also limit consumption by non-target species. 314 
HPO fulfils many requirements of a vaccine carrier: (1) it is palatable, whether presented 315 
alone (S. Gowtage, unpublished results) or with the paste bait; (2) it provides good 316 
adherence and structural compatibility with the paste bait; (3) it provides an environment 317 
for long-term stability of BCG at 20C; and (4) it is solid over the range of temperatures 318 
likely to be encountered in the field (HPO Ph. Eur. drop point specified range 32–43 C). 319 
5. Conclusions  320 
We have developed an oral bait-vaccine delivery system suitable for further evaluation 321 
with captive and wild badgers. Many of these tests are already underway, including 322 
evaluation of the efficacy of oral BCG fed to captive badgers in the context of PT-HPO and 323 
devising a pragmatic protocol for deployment of PT-HPO to wild badgers to maximise bait 324 
uptake. Future work will also comprise the necessary technology transfer for larger-scale 325 
manufacture. BCG was stable in the bait during prolonged periods of storage frozen. BCG 326 
viability declined at 4 C and 20 C but not appreciably until seven days at either 327 
temperature, indicating that BCG may retain sufficient viability during cold storage and field 328 
deployment to make it a viable oral vaccine. However, further studies will be required once 329 
the minimum efficacious dose of the vaccine is determined. 330 
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Fig. 1. Different designs of the PT-HPO bait. As referred to in the text – ‘SH’, ‘M’, ‘C’, ‘T’ 395 
and ‘D’; b) Vertical (top) and horizontal (bottom) sections of a frozen ‘M’ bait showing the 396 
location of the 200µl vaccine payload (arrows). Bar = 1 cm. All baits comprised the same 397 
basic structure in which the vaccine payload was held centrally in the HPO (white lipid); 398 
the IPA was located in the same position for the biomarker study. The HPO containing the 399 
vaccine was surrounded by a PT cylinder (brown paste bait) which in the case of the ‘SH’, 400 
‘M’ and ‘C’ baits was then in turn surrounded by an external layer of HPO. 401 
Abbreviations: PT, paste bait; HPO, hardened peanut oil; IPA, iophenoxic acid. 402 
 403 
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Fig. 2. Mean palatability (%) for each batch of paste bait (n=13). Each bar represents the 405 
mean palatability for a batch of bait and error bars indicate the range in palatability for 406 
each batch. Between 4-6 groups of animals (mean 5.2) consumed bait (>20 g) in each 407 
batch test. The dashed line is the cut-off of 65% below which a batch of bait was 408 
considered to be insufficiently attractive and palatable by the manufacturer. 409 
 410 
  411 
Figure 3: Stability profiles of BCG in vaccine-baits stored under different conditions: (a) -412 
20 °C, (b) 4 °C and (c) 20 °C 98% relative humidity. Data points are the calculated mean 413 
log10 change in CFU/vaccine-bait relative to the mean dose determined before incubation 414 
under the conditions stated. The numbers of vaccine-baits sampled at each point are 415 
indicated above the range error bars (where visible). Vaccine-baits evaluated at 4 °C and 416 
20 °C 98% RH (relative humidity) had previously been stored at -20 °C for between 4 and 417 
207 days, and 25 days, respectively. 418 
 419 
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Fig. 4. Photographs of packaged BCG-PT-HPO vaccine-baits stored at 20 °C and 98% RH 420 
for (a) 2 days and (b) 30 days. There was only limited absorption of water by the exposed 421 
PT component on the surface of the bait (area indicated by the scalpel in ‘b’). 422 
Abbreviations: PT, paste bait; HPO, hardened peanut oil; RH relative humidity. 423 
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